TherapeuticsMD Inkomsten in het verleden

Verleden criteriumcontroles 0/6

TherapeuticsMD is de winst gegroeid met een gemiddeld jaarlijks percentage van 53.7%, terwijl de Pharmaceuticals industrie de winst daalde met 0.2%. De inkomsten zijn gedaald met een gemiddelde van 15.9% per jaar.

Belangrijke informatie

53.7%

Groei van de winst

59.2%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	-15.9%
Rendement op eigen vermogen	-17.5%
Nettomarge	-485.3%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition

Jul 06

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

Jun 16

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

Mar 14

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

Oct 22

TherapeuticsMD: The Long Road To Profitability

Jul 08

TherapeuticsMD drops 3% despite consensus beating Q1 results

May 06

TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?

Feb 24

TherapeuticsMD: Annovera May Save The Day

Feb 04

TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be

Jan 29

What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?

Jan 27

Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?

Dec 30

TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years

Dec 09

TherapeuticsMD: Q3 Report Reveals Strong Rebound And Bolsters Commercial Outlook

Nov 25

Therapeutics MD EPS beats by $0.01, beats on revenue

Nov 09

Opbrengsten en kosten

Hoe TherapeuticsMD geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:TXMD Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	1	-5	6	0
31 Mar 24	1	-6	7	0
31 Dec 23	1	-8	9	0
30 Sep 23	69	42	19	0
30 Jun 23	70	29	30	0
31 Mar 23	70	17	42	0
31 Dec 22	70	1	57	0
30 Sep 22	-64	3	-26	-6
30 Jun 22	-39	-30	10	-4
31 Mar 22	-17	-58	48	-2
31 Dec 21	3	-79	73	0
30 Sep 21	91	-172	194	8
30 Jun 21	85	-157	182	8
31 Mar 21	72	-166	178	9
31 Dec 20	65	-184	193	10
30 Sep 20	58	-191	198	12
30 Jun 20	63	-190	204	15
31 Mar 20	58	-193	196	17
31 Dec 19	50	-176	175	20
30 Sep 19	39	-166	157	22
30 Jun 19	19	-170	142	25
31 Mar 19	16	-148	130	27
31 Dec 18	16	-133	116	27
30 Sep 18	15	-115	95	32
30 Jun 18	16	-94	76	31
31 Mar 18	17	-80	62	33
31 Dec 17	17	-77	58	34
30 Sep 17	17	-78	60	33
30 Jun 17	18	-89	63	41
31 Mar 17	18	-90	59	47
31 Dec 16	19	-90	51	54
30 Sep 16	20	-85	44	57
30 Jun 16	20	-79	36	59
31 Mar 16	21	-85	32	69
31 Dec 15	20	-85	29	72
30 Sep 15	19	-84	26	73
30 Jun 15	18	-82	25	71
31 Mar 15	17	-66	23	55
31 Dec 14	15	-54	22	43
30 Sep 14	14	-46	21	35
30 Jun 14	12	-36	20	24
31 Mar 14	10	-31	20	18
31 Dec 13	9	-28	19	14

Kwaliteitswinsten: TXMD is momenteel verliesgevend.

Groeiende winstmarge: TXMD is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: TXMD is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 53.7% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van TXMD over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: TXMD is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 12.7% ).

Rendement op eigen vermogen

Hoge ROE: TXMD heeft een negatief Return on Equity ( -17.47% ), omdat het momenteel verliesgevend is.

TherapeuticsMD Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023)

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Recent updates

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023)

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD raises $7M in private placement

Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board

TherapeuticsMD appoints interim co-CEOs

TherapeuticsMD, Inc. Appoints Justin Roberts as A Director

Therapeutics MD Q2 Earnings Preview

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

TherapeuticsMD receives $15M equity investment from Rubric Capital

TherapeuticsMD jumps 12% as top investor discloses insider purchase

Essex Woodlands Management, Inc. cancelled the acquisition of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD plunges 42% as merger agreement ends

TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from NASDAQ Biotechnology Index

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

TherapeuticsMD’s Common Stock No Longer Be Listed on Any Public Market Upon Completion of Transaction with EW Healthcare Partners

Essex Woodlands Management, Inc. entered into a definitive merger agreement to acquire TherapeuticsMD, Inc. (NasdaqGS:TXMD) for $93 million.

Consensus forecasts updated

Therapeuticsmd, Inc. Receives U.S. Food and Drug Administration (Fda) Approval for Supplemental New Drug Application (Snda) for Annovera®

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Consensus forecasts updated

Price target decreased to US$3.75

Co-Founder notifies of intention to sell stock

Forecast breakeven date pushed back to 2024

GoodRx Holdings, Inc. (NasdaqGS:GDRX) completed the acquisition of Vitacare Prescription Services, Inc from from TherapeuticsMD, Inc. (NasdaqGS:TXMD) for approximately $160 million.

Co-Founder notifies of intention to sell stock

Consensus revenue estimates fall by 24%

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Robert G. Finizio Notifies TherapeuticsMD, Inc. of His Decision to Resign from the Board of Directors of the Company and as Vice Chair

Independent Director recently bought US$579k worth of stock

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Forecast to breakeven in 2023

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

Executive Vice President of Operations Edward Borkowski has left the company

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Independent Director recently bought US$725k worth of stock

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)

No longer forecast to breakeven

TherapeuticsMD: The Long Road To Profitability

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from Russell 3000E Value Index

TherapeuticsMD, Inc. Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

Co-Founder exercised options and sold US$70k worth of stock

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)

TherapeuticsMD drops 3% despite consensus beating Q1 results

Revenue and earnings beat expectations

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)

TherapeuticsMD, Inc. to Report Q4, 2020 Results on Mar 02, 2021

TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

TherapeuticsMD: Annovera May Save The Day

Price target raised to US$8.00

TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be

What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?

New 90-day high: US$1.61

Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?

TherapeuticsMD, Inc. Announces the Launch of Just Say Vagina to Encourage Women to Speak Clearly and Directly About Their Reproductive Health

TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years

New 90-day low: US$1.21

Price target raised to US$8.20

TherapeuticsMD: Q3 Report Reveals Strong Rebound And Bolsters Commercial Outlook